CDK2 and cancer: We then generated an ADC by conjugating SNS-032, known to have selective inhibition of CDK2/7/9 over CDK4/6 (25), to cetuximab, through a maleimide-based linker, using the antibody as a vehicle to specifically deliver the inhibitor to cancer cells.